Neoadjuvant Combination Treatment with Checkpoint Inhibitors, Chemotherapy, and BRAF/MEK Inhibitors for BRAFV600E Glioblastoma Results in Sustained Response: A Case Report
Naveed Wagle, Akanksha Sharma, Minhdan Nguyen, J. Truong, Tiffany M Juarez, Santosh Kesari
{"title":"Neoadjuvant Combination Treatment with Checkpoint Inhibitors, Chemotherapy, and BRAF/MEK Inhibitors for BRAFV600E Glioblastoma Results in Sustained Response: A Case Report","authors":"Naveed Wagle, Akanksha Sharma, Minhdan Nguyen, J. Truong, Tiffany M Juarez, Santosh Kesari","doi":"10.1093/noajnl/vdae110","DOIUrl":null,"url":null,"abstract":"\n Radiation’s confounding and adverse effects on tumor microenvironment and normal brain could potentially be delayed by upfront combination treatment. We present a patient with newly diagnosed BRAFV600E-mutant, PD-L1-positive glioblastoma treated with off-label RAF/MEK inhibitors encorafenib/binimetinib after progressing on postoperative immune checkpoint blockade and temozolomide (no radiation administered: NCT03425292). Complete response occurred six months after adding encorafenib/binimetinib, and clinical benefit was sustained for over 20 months. Treatment was well-tolerated with manageable toxicities, with quality of life and cognitive function maintained throughout treatment. Adding encorafenib/binimetinib to immunotherapy and temozolomide conferred favorable and lasting efficacy for our BRAFV600E-mutant glioblastoma patient, justifying future studies.","PeriodicalId":3,"journal":{"name":"ACS Applied Electronic Materials","volume":"65 4","pages":""},"PeriodicalIF":4.7000,"publicationDate":"2024-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Electronic Materials","FirstCategoryId":"0","ListUrlMain":"https://doi.org/10.1093/noajnl/vdae110","RegionNum":3,"RegionCategory":"材料科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENGINEERING, ELECTRICAL & ELECTRONIC","Score":null,"Total":0}
引用次数: 0
Abstract
Radiation’s confounding and adverse effects on tumor microenvironment and normal brain could potentially be delayed by upfront combination treatment. We present a patient with newly diagnosed BRAFV600E-mutant, PD-L1-positive glioblastoma treated with off-label RAF/MEK inhibitors encorafenib/binimetinib after progressing on postoperative immune checkpoint blockade and temozolomide (no radiation administered: NCT03425292). Complete response occurred six months after adding encorafenib/binimetinib, and clinical benefit was sustained for over 20 months. Treatment was well-tolerated with manageable toxicities, with quality of life and cognitive function maintained throughout treatment. Adding encorafenib/binimetinib to immunotherapy and temozolomide conferred favorable and lasting efficacy for our BRAFV600E-mutant glioblastoma patient, justifying future studies.
期刊介绍：
ACS Applied Electronic Materials is an interdisciplinary journal publishing original research covering all aspects of electronic materials. The journal is devoted to reports of new and original experimental and theoretical research of an applied nature that integrate knowledge in the areas of materials science, engineering, optics, physics, and chemistry into important applications of electronic materials. Sample research topics that span the journal's scope are inorganic, organic, ionic and polymeric materials with properties that include conducting, semiconducting, superconducting, insulating, dielectric, magnetic, optoelectronic, piezoelectric, ferroelectric and thermoelectric.
Indexed/Abstracted：
Web of Science SCIE
Scopus
CAS
INSPEC
Portico
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
